Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply

The EPIC study investigators were aware of the prior cardiac studies cited by Drs Kenter and Cohen suggesting nephrotoxicity due to poloxamer 188. It is important to note that these early studies used commercial-grade poloxamer 188. Subsequent studies showed that removal of impurities from this prep...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA : the journal of the American Medical Association 2021-09, Vol.326 (10), p.974
Hauptverfasser: Kenter, Marcel J H, Cohen, Adam F, Gurkan, Umut A, Casella, James F, Kronsberg, Shari S, Gorney, Rebecca T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 10
container_start_page 974
container_title JAMA : the journal of the American Medical Association
container_volume 326
creator Kenter, Marcel J H
Cohen, Adam F
Gurkan, Umut A
Casella, James F
Kronsberg, Shari S
Gorney, Rebecca T
description The EPIC study investigators were aware of the prior cardiac studies cited by Drs Kenter and Cohen suggesting nephrotoxicity due to poloxamer 188. It is important to note that these early studies used commercial-grade poloxamer 188. Subsequent studies showed that removal of impurities from this preparation reduced nephrotoxicity in a rat model and that the isolated impurities caused nephrotoxity. A phase 1 study of the resulting purified poloxamer 188 for acute chest syndrome in 43 participants with SCD focused on safety and included studies of urinary N-acetylglucosaminidase, retinol-binding protein, creatinine and creatinine clearance, albumin, and IgG excretion; participants were followed up for up to 10 days with repeat measurements at 28 to 35 days. The investigators concluded that there were no time-related increases in serum creatinine or creatinine clearance and no evidence of adverse effects on glomerular integrity, permeability, filtration, or proximal or distal tubular function. Phase 2 and 3 studies of purified poloxamer 188 for vaso-occlusive episodes in SCD also showed no evidence of nephrotoxicity based on serum creatinine levels. The effects of poloxamer 188 on the kidney are more fully explained in Supplement 3 of our article.
doi_str_mv 10.1001/jama.2021.11097
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2577528239</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2577528239</sourcerecordid><originalsourceid>FETCH-proquest_journals_25775282393</originalsourceid><addsrcrecordid>eNrdjb1OwzAURg0CifAzs16JOamdNLIzolDEwBDRCsbKJDeqw60dfJMK3p4OPAAz33KGc6RPiFslMyWlWgx2b7Nc5ipTSlb6VCSqLExalJU5E4mUlUn10iwvxCXzII9ThU5OnptA4cvuMYIyBg4MDdkW3wP0IUJjne9nglfLIQ1tSzO7A8JqdBw6ZHAe6p2jLqIH6zu472aaGN7ctIO1az8IoUYieHCMlnHxb8_SFxzp-1qc95YYb355Je4eV5v6KR1j-JyRp-0Q5uiPapuXWpe5yYuq-Fv1A_fpniA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2577528239</pqid></control><display><type>article</type><title>Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply</title><source>American Medical Association Journals</source><creator>Kenter, Marcel J H ; Cohen, Adam F ; Gurkan, Umut A ; Casella, James F ; Kronsberg, Shari S ; Gorney, Rebecca T</creator><creatorcontrib>Kenter, Marcel J H ; Cohen, Adam F ; Gurkan, Umut A ; Casella, James F ; Kronsberg, Shari S ; Gorney, Rebecca T</creatorcontrib><description>The EPIC study investigators were aware of the prior cardiac studies cited by Drs Kenter and Cohen suggesting nephrotoxicity due to poloxamer 188. It is important to note that these early studies used commercial-grade poloxamer 188. Subsequent studies showed that removal of impurities from this preparation reduced nephrotoxicity in a rat model and that the isolated impurities caused nephrotoxity. A phase 1 study of the resulting purified poloxamer 188 for acute chest syndrome in 43 participants with SCD focused on safety and included studies of urinary N-acetylglucosaminidase, retinol-binding protein, creatinine and creatinine clearance, albumin, and IgG excretion; participants were followed up for up to 10 days with repeat measurements at 28 to 35 days. The investigators concluded that there were no time-related increases in serum creatinine or creatinine clearance and no evidence of adverse effects on glomerular integrity, permeability, filtration, or proximal or distal tubular function. Phase 2 and 3 studies of purified poloxamer 188 for vaso-occlusive episodes in SCD also showed no evidence of nephrotoxicity based on serum creatinine levels. The effects of poloxamer 188 on the kidney are more fully explained in Supplement 3 of our article.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.2021.11097</identifier><language>eng</language><publisher>Chicago: American Medical Association</publisher><subject>Adults ; Albumins ; Children ; Clearances ; Creatinine ; Immunoglobulin G ; Impurities ; Kidneys ; N-Acetylglucosaminidase ; Permeability ; Placebos ; Poloxamers ; Retinol-binding protein ; Sickle cell disease ; Vitamin A</subject><ispartof>JAMA : the journal of the American Medical Association, 2021-09, Vol.326 (10), p.974</ispartof><rights>Copyright American Medical Association Sep 14, 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Kenter, Marcel J H</creatorcontrib><creatorcontrib>Cohen, Adam F</creatorcontrib><creatorcontrib>Gurkan, Umut A</creatorcontrib><creatorcontrib>Casella, James F</creatorcontrib><creatorcontrib>Kronsberg, Shari S</creatorcontrib><creatorcontrib>Gorney, Rebecca T</creatorcontrib><title>Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply</title><title>JAMA : the journal of the American Medical Association</title><description>The EPIC study investigators were aware of the prior cardiac studies cited by Drs Kenter and Cohen suggesting nephrotoxicity due to poloxamer 188. It is important to note that these early studies used commercial-grade poloxamer 188. Subsequent studies showed that removal of impurities from this preparation reduced nephrotoxicity in a rat model and that the isolated impurities caused nephrotoxity. A phase 1 study of the resulting purified poloxamer 188 for acute chest syndrome in 43 participants with SCD focused on safety and included studies of urinary N-acetylglucosaminidase, retinol-binding protein, creatinine and creatinine clearance, albumin, and IgG excretion; participants were followed up for up to 10 days with repeat measurements at 28 to 35 days. The investigators concluded that there were no time-related increases in serum creatinine or creatinine clearance and no evidence of adverse effects on glomerular integrity, permeability, filtration, or proximal or distal tubular function. Phase 2 and 3 studies of purified poloxamer 188 for vaso-occlusive episodes in SCD also showed no evidence of nephrotoxicity based on serum creatinine levels. The effects of poloxamer 188 on the kidney are more fully explained in Supplement 3 of our article.</description><subject>Adults</subject><subject>Albumins</subject><subject>Children</subject><subject>Clearances</subject><subject>Creatinine</subject><subject>Immunoglobulin G</subject><subject>Impurities</subject><subject>Kidneys</subject><subject>N-Acetylglucosaminidase</subject><subject>Permeability</subject><subject>Placebos</subject><subject>Poloxamers</subject><subject>Retinol-binding protein</subject><subject>Sickle cell disease</subject><subject>Vitamin A</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNrdjb1OwzAURg0CifAzs16JOamdNLIzolDEwBDRCsbKJDeqw60dfJMK3p4OPAAz33KGc6RPiFslMyWlWgx2b7Nc5ipTSlb6VCSqLExalJU5E4mUlUn10iwvxCXzII9ThU5OnptA4cvuMYIyBg4MDdkW3wP0IUJjne9nglfLIQ1tSzO7A8JqdBw6ZHAe6p2jLqIH6zu472aaGN7ctIO1az8IoUYieHCMlnHxb8_SFxzp-1qc95YYb355Je4eV5v6KR1j-JyRp-0Q5uiPapuXWpe5yYuq-Fv1A_fpniA</recordid><startdate>20210914</startdate><enddate>20210914</enddate><creator>Kenter, Marcel J H</creator><creator>Cohen, Adam F</creator><creator>Gurkan, Umut A</creator><creator>Casella, James F</creator><creator>Kronsberg, Shari S</creator><creator>Gorney, Rebecca T</creator><general>American Medical Association</general><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20210914</creationdate><title>Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply</title><author>Kenter, Marcel J H ; Cohen, Adam F ; Gurkan, Umut A ; Casella, James F ; Kronsberg, Shari S ; Gorney, Rebecca T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_25775282393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adults</topic><topic>Albumins</topic><topic>Children</topic><topic>Clearances</topic><topic>Creatinine</topic><topic>Immunoglobulin G</topic><topic>Impurities</topic><topic>Kidneys</topic><topic>N-Acetylglucosaminidase</topic><topic>Permeability</topic><topic>Placebos</topic><topic>Poloxamers</topic><topic>Retinol-binding protein</topic><topic>Sickle cell disease</topic><topic>Vitamin A</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kenter, Marcel J H</creatorcontrib><creatorcontrib>Cohen, Adam F</creatorcontrib><creatorcontrib>Gurkan, Umut A</creatorcontrib><creatorcontrib>Casella, James F</creatorcontrib><creatorcontrib>Kronsberg, Shari S</creatorcontrib><creatorcontrib>Gorney, Rebecca T</creatorcontrib><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kenter, Marcel J H</au><au>Cohen, Adam F</au><au>Gurkan, Umut A</au><au>Casella, James F</au><au>Kronsberg, Shari S</au><au>Gorney, Rebecca T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><date>2021-09-14</date><risdate>2021</risdate><volume>326</volume><issue>10</issue><spage>974</spage><pages>974-</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><abstract>The EPIC study investigators were aware of the prior cardiac studies cited by Drs Kenter and Cohen suggesting nephrotoxicity due to poloxamer 188. It is important to note that these early studies used commercial-grade poloxamer 188. Subsequent studies showed that removal of impurities from this preparation reduced nephrotoxicity in a rat model and that the isolated impurities caused nephrotoxity. A phase 1 study of the resulting purified poloxamer 188 for acute chest syndrome in 43 participants with SCD focused on safety and included studies of urinary N-acetylglucosaminidase, retinol-binding protein, creatinine and creatinine clearance, albumin, and IgG excretion; participants were followed up for up to 10 days with repeat measurements at 28 to 35 days. The investigators concluded that there were no time-related increases in serum creatinine or creatinine clearance and no evidence of adverse effects on glomerular integrity, permeability, filtration, or proximal or distal tubular function. Phase 2 and 3 studies of purified poloxamer 188 for vaso-occlusive episodes in SCD also showed no evidence of nephrotoxicity based on serum creatinine levels. The effects of poloxamer 188 on the kidney are more fully explained in Supplement 3 of our article.</abstract><cop>Chicago</cop><pub>American Medical Association</pub><doi>10.1001/jama.2021.11097</doi></addata></record>
fulltext fulltext
identifier ISSN: 0098-7484
ispartof JAMA : the journal of the American Medical Association, 2021-09, Vol.326 (10), p.974
issn 0098-7484
1538-3598
language eng
recordid cdi_proquest_journals_2577528239
source American Medical Association Journals
subjects Adults
Albumins
Children
Clearances
Creatinine
Immunoglobulin G
Impurities
Kidneys
N-Acetylglucosaminidase
Permeability
Placebos
Poloxamers
Retinol-binding protein
Sickle cell disease
Vitamin A
title Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T00%3A24%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Poloxamer%20188%20vs%20Placebo%20for%20Painful%20Vaso-occlusive%20Episodes%20in%20Children%20and%20Adults%20With%20Sickle%20Cell%20Disease/Poloxamer%20188%20vs%20Placebo%20for%20Painful%20Vaso-occlusive%20Episodes%20in%20Children%20and%20Adults%20With%20Sickle%20Cell%20Disease/Poloxamer%20188%20vs%20Placebo%20for%20Painful%20Vaso-occlusive%20Episodes%20in%20Children%20and%20Adults%20With%20Sickle%20Cell%20Disease-Reply&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Kenter,%20Marcel%20J%20H&rft.date=2021-09-14&rft.volume=326&rft.issue=10&rft.spage=974&rft.pages=974-&rft.issn=0098-7484&rft.eissn=1538-3598&rft_id=info:doi/10.1001/jama.2021.11097&rft_dat=%3Cproquest%3E2577528239%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2577528239&rft_id=info:pmid/&rfr_iscdi=true